e-learning
resources
Amsterdam 2011
Monday, 26.09.2011
Palliation and morbidity in lung cancer patients
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Potential role of antidepressants as part of anticancer therapy
D. Jovanovic, R. Stevic, S. Popevic, M. Velinovic, N. Samardzic, D. Maric (Belgrade, Republic Of Serbia)
Source:
Annual Congress 2011 - Palliation and morbidity in lung cancer patients
Session:
Palliation and morbidity in lung cancer patients
Session type:
Thematic Poster Session
Number:
2767
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
D. Jovanovic, R. Stevic, S. Popevic, M. Velinovic, N. Samardzic, D. Maric (Belgrade, Republic Of Serbia). Potential role of antidepressants as part of anticancer therapy. Eur Respir J 2011; 38: Suppl. 55, 2767
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Imaging of complicated pneumonia: what is new?
Related content which might interest you:
Novel anti-inflammatory agents
Source: Annual Congress 2009 - Emerging trends in the therapy of COPD
Year: 2009
The role of somatostatin analogues in combination to antineoplastic agents in the treatment of SCLC patients (preliminary findings)
Source: Annual Congress 2009 - Management of thoracic malignancies
Year: 2009
How to disrupt malicious LC-fILD pathways: antifibrotic agents as a promising therapeutic approach
Source: Virtual Congress 2021 – Lung cancer and fibrotic interstitial lung diseases: a challenging association for pulmonologists
Year: 2021
Inhalations of ultra-low doses of alkylating drug for the treatment of steroid-dependant asthma: anti-inflammatory effect of therapy
Source: Eur Respir J 2001; 18: Suppl. 33, 266s
Year: 2001
Reasons for hepatotoxic reactions to chemotherapeutic agents and possibilities of their prevention in adolescents with tuberculosis
Source: Eur Respir J 2001; 18: Suppl. 33, 468s
Year: 2001
Systemic therapies: optimising the sequences of chemotherapies, targeted therapies and immunotherapies
Source: International Congress 2017 – PG1 Re-defining the role of chest physicians in lung cancer: new opportunities in diagnostics and therapy
Year: 2017
The nephrotoxic effect assesment of tuberculostatic drugs therapy by urinary enzymes
Source: Eur Respir J 2004; 24: Suppl. 48, 654s
Year: 2004
Novel targets and emerging therapies in MPM
Source: ERS Skills course: Multi-disciplinary care in thoracic oncology
Year: 2019
Late Breaking Abstract - Anti-inflammatory activity of novel transtilbene sulfonamide analogues as potential novel therapeutic agents for inflammatory lung disease
Source: International Congress 2019 – COPD treatment: cardiovascular, oxygen and vaccination studies
Year: 2019
Next generation of anti-inflammatory therapy for COPD?
Source: Eur Respir J, 50 (4) 1702084; 10.1183/13993003.02084-2017
Year: 2017
Antibiotics as immunomodulators: a potential pharmacologic approach for ARDS treatment
Source: Eur Respir Rev, 30 (162) 210093; 10.1183/16000617.0093-2021
Year: 2021
Correlation of response to antifibrotic treatment with adverse events to antifibrotic drugs in IPF patients from the real-world EMPIRE registry
Source: Virtual Congress 2020 – Translational aspects of idiopathic pulmonary fibrosis
Year: 2020
Therapeutic effects of topical calcilytic in IgE/Th2 and alarmin-driven surrogates of human asthma
Source: International Congress 2019 – Novel targets and mechanisms in asthma
Year: 2019
Clinical implications and opportunities for new drug therapies
Source: Annual Congress 2008 - Deadly networks: disease-causing protein and DNA modifications
Year: 2008
Clinical implications and novel therapies
Source: International Congress 2018 – Accelerated ageing in lungs
Year: 2018
Lung disease induced by novel chemotherapeutic agents and biomolecules
Source: Annual Congress 2006 - Drug-induced lung injury – new aspects
Year: 2006
Role of altered immune response in CF and implication for antiinflammatory therapies
Source: Research Seminar 2012 - Pulmonary inflammation in paediatric respiratory disease
Year: 2012
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept